WASHINGTON (AP) — Shares of Jazz Pharmaceuticals rose Wednesday after analysts shrugged off the company's disappointing second-quarter results and focused on higher full-year guidance for 2013.

THE SPARK: Jazz said late Tuesday that its adjusted income rose more than 30 percent to $1.43 per share in the three months ended June 30. But that was below analysts' average estimate of $1.52 per share, according to FactSet.

Despite the missed earnings, company management boosted its full-year earnings per share forecast to between $6.10 and $6.30 per share from $6.20 to $6.40 per share. It now expects revenue of $860 million to $880 million, up from $830 million to $860 million. Wall Street was expecting earnings of $6.22 per share, on average, on sales of $852.6 million.

THE ANALYSIS: Cantor Fitzgerald analyst Irina Rivkind reiterated a "Buy" rating on the stock, stating that company shares should trade higher in coming months.

"The earnings miss can be attributed to increased investment into the business — a welcome change from other companies who cut costs to make their bottom line," Rivkind said in a note to investors.

THE BACKGROUND: Dublin-based Jazz markets the narcolepsy treatment Xyrem. The drug is Jazz's best-selling product, but the company warned in May that rival Roxane Laboratories could win approval from the Food and Drug Administration for a generic version of the drug. Jazz has been suing Roxane over the company's application for the generic drug since 2010.

Jazz raised 2013 Xyrem sales guidance to between $560 million and $570 million, from $540 million and $555 million. The company also said it obtained two new patents on Xyrem, which could help protect the drug from generic competition.

SHARE ACTION: Shares of Jazz Pharmaceuticals Public Limited Company rose $1.99, or 2.6 percent, to $79.98 in midday trading, after earlier jumping as high as $80.22..

About News.net

Publishing Services International Limited (PSIL) is the publisher and operator of a worldwide network of online news sites dedicated to delivering fair, accurate and relevant reporting from a variety of the world’s most trusted sources – from the biggest cities to the smallest towns.

We deliver positive and powerful messages to our readers, providing up‑to‑the‑second news that matters to the individual.

Our promise is to serve communities and individuals worldwide, delivering information that hasn’t always been available to them. We will give them back a voice – a voice that’s empowering because it is theirs – and provide a platform to communicate between themselves and the world.

We believe people are not just generic demographics; they are individuals with their own preferences and curiosities. We are about understanding these individuals, listening to them, and serving them.

We are the new pioneering spirit of news – we’re not talking to everyone, we’re talking with every one.

If you want your news, your voice, your way, on your time – we’ve got news for you.

 

FAQs

Email

If you have any questions or concerns please email us on support@news.net

Phone

  • Australia, Toll Free 1-800-983-421
  • Hong Kong, Toll Free 800-906-187
  • Singapore, Toll Free 800-852-3871
  • USA/Canada, Toll Free 1-800-830-4132

Advertise With Us

Interested in being awesome?
Contact us by email or phone.

Cancel